Dare Bioscience Receives Nasdaq Delisting Notice Over Equity Shortfall
DARE sits 54% above its 52-week low of $1.27 on light trading volume (0.2× avg).
Summary
Dare Bioscience received a Nasdaq delisting notice on July 13, 2026, after its stockholders' equity fell below the required $2.5 million. The company plans to request a hearing to stay the delisting, but compliance is uncertain.
Key Events · Legal and Risk Events · DARE
-
Nasdaq Delisting Notice Received
On July 13, 2026, Nasdaq notified Dare Bioscience that it fails to meet the $2.5 million stockholders' equity requirement under Listing Rule 5550(b), based on its Q1 2026 10-Q.
-
Alternative Listing Standards Not Met
As of July 13, 2026, the company also does not satisfy the alternative requirements of $35 million market value of listed securities or $500,000 net income from continuing operations.
-
Hearing Request to Stay Delisting
Dare intends to timely request a hearing before a Nasdaq Hearing Panel, which will stay the suspension and delisting pending the panel's decision and any granted extension.
-
Compliance Uncertainty
There is no assurance the panel will grant an extension or that the company will regain compliance; failure to maintain listing could severely impact liquidity and capital access.
Analysis · DARE · Life Sciences
Dare Bioscience has been notified by Nasdaq that it no longer meets the minimum $2.5 million stockholders' equity requirement for continued listing. The company's Q1 2026 10-Q reported equity below that threshold, and as of July 13, 2026, it also fails the alternative tests of $35 million market value or $500,000 net income. While Dare intends to request a hearing — which temporarily stays delisting — there is no guarantee the panel will grant an extension or that the company can regain compliance. This comes just weeks after shareholders approved a 1.5 million share increase to the incentive plan and an $11.7 million capital raise, underscoring the urgency of its cash position. A delisting would severely impair liquidity and access to capital, threatening the commercial launch of its recently approved products.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DARE was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $1.27 to $3.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.